May 15, 2013 | Instem has acquired Logos Technologies, representing its strategic move into the early phase clinical trials market. Logos’ ALPHADAS software solution suite is a proactive eSource clinical trials system that is mobile, schedule-driven, and provides real-time bedside or station based direct data capture that virtually eliminates paper-based data. ALPHADAS delivers enhanced quality, operational efficiencies and time savings across the clinic, data management, recruitment, site administration and the laboratory. “One of the value-added offerings this acquisition will bring is the introduction of a Software-as-a-Service (SaaS) version of ALPHADAS, which will be especially useful for the many small clinical units within the early phase market,” Instem said in a statement. “Instem’s SaaS model offers simpler, more cost effective ways to provide software functionality, maintenance, and support over the Internet.” Press Release